Reactive Oxygen® technology is a novel antimicrobial platform creating treatments for chronic and acute indications with potent antimicrobial qualities, potential for biofilm penetration, tissue regeneration, immune system stimulation and potential efficacy against Gram-positive and Gram-negative pathogenic bacteria, as well as pathogenic fungi and viruses.

With the World Health Organization predicting that millions may die due to global antimicrobial resistance (AMR), Reactive Oxygen® technology offers a potential solution to the global AMR threat which can help save lives.


Matoke® Holdings Ltd is a member of the BioIndustry Association (BIA) and registered Small or Medium-sized Enterprise (SME) with the European Medicines Agency (EMA). 

Matoke® Pharma

Matoke® Pharma leads on the research and development of our pharmceutical products.


Our Medical Device division leads on the distribution of Surgihoney™RO®.